Press Releases

Press releases

Empros phase 2b obesity trial enrollment complete in only one month..

Press releases

Empros pharma doses first patients in large scale clinical study of anti-obesity drug EMP-16

Press releases

Empros secures 80 msek funding to support development of obesity treatment candidate – EMP 16

Press releases

Empros enters late stage clinical development of obesity treatment EMP16

Press releases

Empros and Megapharm announce letter of intent

Press releases

Securing 40 msek investment

Press releases

Results from phase IIA trial published in major scientific journal

Press releases

Annual general meeting

Press releases

Pharmacokinetics publication

Press releases

Recruitment complete; Empros second clinical trial

Press releases

Empros first clinical trial published

Press releases

Empros Pharma strengthen the board of directors

Press releases

Empros Pharma raises sek 40M to fully finance the upcoming proof-of-concept trial for its primary drug candidate EMP16

Press releases

Empros pharma tar in 40 msek och säkrar finansieringen av proof-of-concept-studie för EMP16

Press releases

Empros Pharma participates in Bio-Korea

Press releases

Empros CEO Arvid Söderhäll interviewed

Press releases

Pressrelease phase 2A trial

Press releases

Meet Empros in New York

Press releases

Meet Empros at Bio Europe

Press releases

Meet Empros Pharma at NLS Days

Press releases

Phase 2A trial concluded

22/02/2024

Empros phase 2b obesity trial enrollment complete in only one month..

25/05/2023

Empros pharma doses first patients in large scale clinical study of anti-obesity drug EMP-16

03/05/2023

Empros secures 80 msek funding to support development of obesity treatment candidate – EMP 16

24/04/2023

Empros enters late stage clinical development of obesity treatment EMP16

20/01/2023

Empros and Megapharm announce letter of intent

06/01/2023

Securing 40 msek investment

20/09/2022

Results from phase IIA trial published in major scientific journal

02/05/2022

Annual general meeting

15/02/2021

Pharmacokinetics publication

31/08/2020

Recruitment complete; Empros second clinical trial

20/04/2020

Empros first clinical trial published

18/03/2020

Empros Pharma strengthen the board of directors

04/07/2019

Empros Pharma raises sek 40M to fully finance the upcoming proof-of-concept trial for its primary drug candidate EMP16

03/07/2019

Empros pharma tar in 40 msek och säkrar finansieringen av proof-of-concept-studie för EMP16

21/06/2018

Empros Pharma participates in Bio-Korea

19/01/2018

Empros CEO Arvid Söderhäll interviewed

11/09/2017

Pressrelease phase 2A trial

07/09/2017

Meet Empros in New York

07/09/2017

Meet Empros at Bio Europe

13/08/2017

Meet Empros Pharma at NLS Days

13/08/2017

Press Releases

Empros phase 2b obesity trial enrollment complete in only one month..

Empros pharma doses first patients in large scale clinical study of anti-obesity drug EMP-16

Empros secures 80 msek funding to support development of obesity treatment candidate – EMP 16

Empros enters late stage clinical development of obesity treatment EMP16

Empros and Megapharm announce letter of intent

Securing 40 msek investment

Results from phase IIA trial published in major scientific journal

Annual general meeting

Pharmacokinetics publication

Recruitment complete; Empros second clinical trial

Empros first clinical trial published

Empros Pharma strengthen the board of directors

Empros Pharma raises sek 40M to fully finance the upcoming proof-of-concept trial for its primary drug candidate EMP16

Empros pharma tar in 40 msek och säkrar finansieringen av proof-of-concept-studie för EMP16

Empros Pharma participates in Bio-Korea

Empros CEO Arvid Söderhäll interviewed

Pressrelease phase 2A trial

Meet Empros in New York

Meet Empros at Bio Europe

Meet Empros Pharma at NLS Days

Phase 2A trial concluded

Pages

Contact